Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;15(4):340-345.
doi: 10.2174/1573399815666190226150402.

Review of Diabetic Polyneuropathy: Pathogenesis, Diagnosis and Management According to the Consensus of Egyptian Experts

Affiliations
Review

Review of Diabetic Polyneuropathy: Pathogenesis, Diagnosis and Management According to the Consensus of Egyptian Experts

Fahmy Amara et al. Curr Diabetes Rev. 2019.

Abstract

Diabetic polyneuropathy (DPN) is a complex and multifactorial entity in which various factors besides hyperglycemia play an important role. Symptoms of DPN are sensory, motor or autonomic. Intensive research proved that oxidative stress is the common denominator for the four major destructive pathways of hyperglycemia including increased hexosamine pathway flux, activation of Protein kinase-C (PKC) pathway, increased Advanced Glycated End-products (AGEs) formation, and increased Polyol Pathway flux. National data in Egypt confirms that more than 60% of Egyptian diabetic patients suffer from neuropathy. The most common complications of DPN are Cardiac Autonomic Neuropathy (CAN), diabetic foot and ulcers, neuromuscular disability, and anxiety. In addition, DPN affects the Quality of Life (QoL). According to common clinical practice, the common diagnostic tools are bed-side diagnosis and electrophysiological tests. Early diagnosis is critical to improve the prognosis of DPN and therapeutic intervention in the early phase. In this review, we provide a clear understanding of the pathogenesis, early diagnosis and the good management of DPN. Since the pathogenesis of DPN is multifactorial, its management is based on combination therapy of symptomatic; either pharmacological or non-pharmacological treatments, and pathogenic treatment. Alpha Lipoic Acid (ALA) is a potent anti-oxidant that has several advantages as a pathogenic treatment of DPN. So, in clinical practice, ALA may be prescribed for patients with early neuropathic deficits and symptoms. Patient education has an important role in the managemement of DPN.

Keywords: Diabetic polyneuropathy; diagnosis; management; pathogenesis; prevalence; protein kinase-C..

PubMed Disclaimer

Similar articles

Cited by

References

    1. Perez-Matos M., Morales-Alvarez M., Mendivil C. Lipids: A suitable therapeutic target in diabetic neuropathy? J. Diabetes Res. 2017;2017:6943851. - PMC - PubMed
    1. Nukada H. Diabetes and the Nervous System. 3rd ed. Elsevier Science . Ischemia and diabetic neuropathy. 2014;126:469–87. - PubMed
    1. Allen M., Doherty T., Rice C., Kimpinski K. Physiology in Medicine: neuromuscular consequences of diabetic neuropathy. J. Appl. Physiol. 2016;121(1):1–6. - PMC - PubMed
    1. Sun M., Zhang M., Shen J., Yan J., Zhou B. Critical appraisal of international guidelines for the management of diabetic neuropathy: is there global agreement in the internet era? Int. J. Endocrinol. 2015:1–11. - PMC - PubMed
    1. Sung J-Y., Tani J., Chang T-S., Lin C.S-Y. Uncovering sensory ax-onal dysfunction in asymptomatic type 2 diabetic neuropathy. PLoS One. 2017;12(2):e0171223. - PMC - PubMed